Rollo Press

Rollo Press

Auto-generated profile, based on publicly available information

Rollo Press

School of Medicine, Medical Sciences, and Nutrition, Foresterhill, Aberdeen, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TLTatiana Langerová
Tatiana Langerová
EMEmma MacVicar
Emma MacVicar
RPRollo Press
Rollo Press
FRFiona L. Read
Fiona L. Read
MPMattia Piana
Mattia Piana
JGJenna M. Gregory
Jenna M. Gregory
Background: Disease-modifying therapies for neurodegenerative disorders are unlikely to succeed once symptoms emerge, as significant neuronal loss has already occurred. Accessible biomarkers that predict disease years in advance, and that can serve as target-engagement readouts for prevention trials, are urgently needed. Methods: We analysed archival gastrointestinal (GI) biopsies from 196 individuals with unexplained GI symptoms and 13–15 years of follow-up. Using sensitive histopathological staining, we assessed misfolded TDP-43, tau, and α-synuclein to test whether peripheral proteinopathies can serve as predictive biomarkers for neurodegeneration. Results: Protein misfolding enteropathy was detected in 60% of cases. Individuals with GI proteinopathy were significantly more likely to develop non-Alzheimer's dementia or α-synucleinopathies, with >80% sensitivity. The presence of two or more proteinopathy markers was associated with a dose-dependent reduction in survival, establishing GI proteinopathy as an independent, life-limiting prognostic factor. Importantly, these pathological changes were present 6.9 years before neurological symptoms emerged. Interpretation: Our findings reveal that neurodegeneration-associated proteinopathies are not confined to the central nervous system but can be detected in routine GI biopsies years before clinical onset. This discovery provides a practical and scalable biomarker platform that could transform early diagnosis, risk stratification, and target-engagement monitoring in clinical trials. Protein misfolding enteropathy represents a new frontier for disease interception in neurodegenerative disorders, enabling intervention at a stage when neuronal damage may still be preventable.